Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
6. GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE
6.1. Overview
6.2. Covert
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3. Overt
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7. GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY
7.1. Overview
7.2. Type A
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3. Type B
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.4. Type C
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8. GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS
8.1. Overview
8.2. Blood Tests
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.3. Liver Function Test
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.4. Detection of Serum Ammonia Levels
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.5. Encephalogram
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.6. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9. GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT
9.1. Overview
9.2. Lactulose
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9.3. Antibiotics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9.4. Probiotics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9.5. Branched-Chain Amino Acids
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9.6. Liver Transplantation
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9.7. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
10. GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER
10.1. Overview
10.2. Hospitals & Clinics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
10.3. Research Institutes
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
10.4. Surgical Centers
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
10.5. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
11. GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY REGION
11.1. Overview
11.2. Americas
11.2.1. North America
11.2.1.1. US
11.2.1.2. Canada
11.2.2. Latin America
11.3. Europe
11.3.1. Western Europe
11.3.1.1. Germany
11.3.1.2. France
11.3.1.3. Italy
11.3.1.4. Spain
11.3.1.5. UK
11.3.1.6. Rest of Western Europe
11.3.2. Eastern Europe
11.4. Asia-Pacific
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. Australia
11.4.5. South Korea
11.4.6. Rest of Asia-Pacific
11.5. Middle East & Africa
11.5.1. Middle East
11.5.2. Africa
12. COMPANY LANDSCAPE
12.1.1. Overview
12.1.2. Competitive Analysis
13. COMPANY PROFILE
13.1. Alfa Wassermann S.P.A
13.1.1. Overview
13.1.2. Product Overview
13.1.3. Financial Overview
13.1.4. Key Developments
13.1.5. SWOT Analysis
13.1.6. Key Strategies
13.2. Cosmo Pharmaceuticals S.P.A
13.2.1. Overview
13.2.2. Product Overview
13.2.3. Financial Overview
13.2.4. Key Developments
13.2.5. SWOT Analysis
13.2.6. Key Strategies
13.3. Horizon Pharma Plc.
13.3.1. Overview
13.3.2. Product Overview
13.3.3. Financial Overview
13.3.4. Key Developments
13.3.5. SWOT Analysis
13.3.6. Key Strategies
13.4. KannaLife Sciences, Inc.
13.4.1. Overview
13.4.2. Product Overview
13.4.3. Financial Overview
13.4.4. Key Developments
13.4.5. SWOT Analysis
13.4.6. Key Strategies
13.5. Ocer Therapeutics
13.5.1. Overview
13.5.2. Product Overview
13.5.3. Financial Overview
13.5.4. Key Developments
13.5.5. SWOT Analysis
13.5.6. Key Strategies
13.6. Rebiotix Inc.
13.6.1. Overview
13.6.2. Product Overview
13.6.3. Financial Overview
13.6.4. Key Developments
13.6.5. SWOT Analysis
13.6.6. Key Strategies
13.7. Spherium Biomed S.L
13.7.1. Overview
13.7.2. Product Overview
13.7.3. Financial Overview
13.7.4. Key Developments
13.7.5. SWOT Analysis
13.7.6. Key Strategies
13.8. Umecrine Cognition AB
13.8.1. Overview
13.8.2. Product Overview
13.8.3. Financial Overview
13.8.4. Key Developments
13.8.5. SWOT Analysis
13.8.6. Key Strategies
13.9. ASKA Pharmaceutical
13.9.1. Overview
13.9.2. Product Overview
13.9.3. Financial Overview
13.9.4. Key Developments
13.9.5. SWOT Analysis
13.9.6. Key Strategies
13.10. Mallinckrodt
13.10.1. Overview
13.10.2. Product Overview
13.10.3. Financial Overview
13.10.4. Key Developments
13.10.5. SWOT Analysis
13.10.6. Key Strategies
13.11. Valeant
13.11.1. Overview
13.11.2. Product Overview
13.11.3. Financial Overview
13.11.4. Key Developments
13.11.5. SWOT Analysis
13.11.6. Key Strategies
13.12. Norgine B.V.
13.12.1. Overview
13.12.2. Product Overview
13.12.3. Financial Overview
13.12.4. Key Developments
13.12.5. SWOT Analysis
13.12.6. Key Strategies
14. APPENDIX
14.1. References
14.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET SYNOPSIS, 2020-2027
TABLE 2 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET ESTIMATES AND FORECAST, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 4 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)
TABLE 5 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
TABLE 6 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 7 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 8 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 9 NORTH AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 10 NORTH AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)
TABLE 11 NORTH AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
TABLE 12 NORTH AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 13 NORTH AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 14 US: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
TABLE 15 US: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)
TABLE 16 US: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
TABLE 17 US: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 18 US: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 19 CANADA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 20 CANADA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)
TABLE 21 CANADA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
TABLE 22 CANADA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 23 CANADA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 24 LATIN AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
TABLE 25 LATIN AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)
TABLE 26 LATIN AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
TABLE 27 LATIN AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 28 LATIN AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 29 EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 30 EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)
TABLE 31 EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
TABLE 32 EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 33 EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 34 WESTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 35 WESTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)
TABLE 36 WESTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
TABLE 37 WESTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 38 WESTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 39 EASTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 40 EASTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)
TABLE 41 EASTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
TABLE 42 EASTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 43 EASTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 44 ASIA-PACIFIC: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 45 ASIA-PACIFIC: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)
TABLE 46 ASIA-PACIFIC: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
TABLE 47 ASIA-PACIFIC: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 48 ASIA-PACIFIC: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE, 2020-2027 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE OF THE GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET
FIGURE 3 MARKET DYNAMICS OF THE GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET
FIGURE 4 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY TYPE, 2020 (%)
FIGURE 5 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY DISEASE SEVERITY, 2020 (%)
FIGURE 6 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY DIAGNOSIS, 2020 (%)
FIGURE 7 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY TREATMENT, 2020 (%)
FIGURE 8 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY END USER, 2020 (%)
FIGURE 9 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY REGION, 2020 (%)
FIGURE 10 NORTH AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 11 EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY REGION, 2020 (%)
FIGURE 12 WESTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 13 ASIA-PACIFIC: OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 14 MIDDLE EAST & AFRICA: OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY REGION, 2020 (%)
FIGURE 15 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 16 ALFA WASSERMANN S.P.A: KEY FINANCIALS
FIGURE 17 ALFA WASSERMANN S.P.A: SEGMENTAL REVENUE
FIGURE 18 ALFA WASSERMANN S.P.A: REGIONAL REVENUE
FIGURE 19 COSMO PHARMACEUTICALS S.P.A: KEY FINANCIALS
FIGURE 20 COSMO PHARMACEUTICALS S.P.A: SEGMENTAL REVENUE
FIGURE 21 COSMO PHARMACEUTICALS S.P.A: REGIONAL REVENUE
FIGURE 22 HORIZON PHARMA PLC.: KEY FINANCIALS
FIGURE 23 HORIZON PHARMA PLC.: SEGMENTAL REVENUE
FIGURE 24 HORIZON PHARMA PLC.: REGIONAL REVENUE
FIGURE 25 KANNALIFE SCIENCES, INC.: KEY FINANCIALS
FIGURE 26 KANNALIFE SCIENCES, INC.: SEGMENTAL REVENUE
FIGURE 27 KANNALIFE SCIENCES, INC.: REGIONAL REVENUE
FIGURE 28 OCER THERAPEUTICS: KEY FINANCIALS
FIGURE 29 OCER THERAPEUTICS: SEGMENTAL REVENUE
FIGURE 30 OCER THERAPEUTICS: REGIONAL REVENUE
FIGURE 31 REBIOTIX INC.: KEY FINANCIALS
FIGURE 32 REBIOTIX INC.: SEGMENTAL REVENUE
FIGURE 33 REBIOTIX INC.: REGIONAL REVENUE
FIGURE 34 SPHERIUM BIOMED S.L: KEY FINANCIALS
FIGURE 35 SPHERIUM BIOMED S.L: SEGMENTAL REVENUE
FIGURE 36 SPHERIUM BIOMED S.L: REGIONAL REVENUE
FIGURE 37 UMECRINE COGNITION AB: KEY FINANCIALS
FIGURE 38 UMECRINE COGNITION AB: SEGMENTAL REVENUE
FIGURE 39 UMECRINE COGNITION AB: REGIONAL REVENUE
FIGURE 40 ASKA PHARMACEUTICAL: KEY FINANCIALS
FIGURE 41 ASKA PHARMACEUTICAL: SEGMENTAL REVENUE
FIGURE 42 ASKA PHARMACEUTICAL: REGIONAL REVENUE
FIGURE 43 MALLINCKRODT: KEY FINANCIALS
FIGURE 44 MALLINCKRODT: SEGMENTAL REVENUE
FIGURE 45 MALLINCKRODT: REGIONAL REVENUE
FIGURE 46 VALEANT: KEY FINANCIALS
FIGURE 47 VALEANT: SEGMENTAL REVENUE
FIGURE 48 VALEANT: REGIONAL REVENUE
FIGURE 49 NORGINE B.V.: KEY FINANCIALS
FIGURE 50 NORGINE B.V.: SEGMENTAL REVENUE
FIGURE 51 NORGINE B.V.: REGIONAL REVENUE
